Matthen Mathew

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Peritoneal Dialysis

Diffuse Large B Cell Lymphoma

Ejection Fraction

Top Venues

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew, Cristina H Messina, Vimal Dave, Xiao Ji, Natalie O Karpinich, Steven Hirschfeld, Marc Ballas, Dan P Zandberg
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII 73 (3) (2024)
John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew, Cristina H Messina, Vimal Dave, Xiao Ji, Natalie O Karpinich, Steven Hirschfeld, Marc Ballas, Dan P Zandberg
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII 73 (3) (2024)
John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew, Cristina H Messina, Vimal Dave, Xiao Ji, Natalie O Karpinich, Steven Hirschfeld, Marc Ballas, Dan P Zandberg
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII 73 (3) (2024)
John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew, Cristina H Messina, Vimal Dave, Xiao Ji, Natalie O Karpinich, Steven Hirschfeld, Marc Ballas, Dan P Zandberg
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII 73 (3) (2024)
John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew, Cristina H Messina, Vimal Dave, Xiao Ji, Natalie O Karpinich, Steven Hirschfeld, Marc Ballas, Dan P Zandberg
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII 73 (3) (2024)